☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - January 2022

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Opicapone (Ongentys®) has been accepted for use as adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations. It is noted that opicapone provides an additional treatment choice in the therapeutic class of catechol-O-methyl transferase inhibitors.

Budesonide (Cortiment®) has been accepted for use in the induction of remission in patients with active microscopic colitis. It is noted that other oral budesonide formulations are available at lower cost.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - January 2022' by emailShare 'SMC Update - January 2022' on FacebookShare 'SMC Update - January 2022' on TwitterShare 'SMC Update - January 2022' on LinkedInShare 'SMC Update - January 2022' on reddit


No Comments to “SMC Update - January 2022”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.